Home Cart Sign in  
Chemical Structure| 718630-59-2 Chemical Structure| 718630-59-2

Structure of PHA-793887
CAS No.: 718630-59-2

Chemical Structure| 718630-59-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

PHA-793887 is a pan-cdk inhibitor, inhibits cdk1/2/4/5/7/9 with IC50s of 5 - 140 nM.

Synonyms: PHA-793887

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of PHA-793887

CAS No. :718630-59-2
Formula : C19H31N5O2
M.W : 361.48
SMILES Code : CC(C)CC(NC1=NNC2=C1CN(C(C3CCN(C)CC3)=O)C2(C)C)=O
Synonyms :
PHA-793887
MDL No. :MFCD17169992
InChI Key :HUXYBQXJVXOMKX-UHFFFAOYSA-N
Pubchem ID :46191454

Safety of PHA-793887

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of PHA-793887

Hedgehog

Isoform Comparison

Biological Activity

Target
  • CDK5

    CDK5/p25, IC50:5 nM

  • CDK4

    CDK4/CyclinD1, IC50:62 nM

  • CDK2

    CDK2/CyclinE, IC50:8 nM

    CDK2/CyclinA, IC50:8 nM

  • CDK9

    CDK9/CyclinT1, IC50:138 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
A549 cells 0.5 µM PHA793887 inhibited the upregulation of TREM2, BLNK, STING1, and CASP1, and induced the activation of caspase-3 PMC8538697
U2OS cells 10 µM 16 h To evaluate the inhibitory effect of PHA-793887 on CDK5-p25 protein-protein interaction, results showed that PHA-793887 significantly reduced the number of BiFC positive cells PMC5865166
Ishikawa cells 10^-6 M 48 h Evaluate the effect of PHA-793887 on Ishikawa cells, results showed that PHA-793887 significantly increased caspase 3/7 activity (p < 0.05). PMC10447446
HEC-1B cells 10^-6 M 48 h Evaluate the effect of PHA-793887 on HEC-1B cells, results showed that PHA-793887 significantly decreased caspase 3/7 activity (p < 0.05). PMC10447446
KLE cells 10^-6 M 48 h Evaluate the effect of PHA-793887 on KLE cells, results showed that PHA-793887 significantly reduced glucose consumption (p < 0.05). PMC10447446

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00996255 Advanced/Metastatic Solid Tumo... More >>rs Less << PHASE1 TERMINATED 2025-02-08 Institut Gustave-Roussy, Ville... More >>juif Cedex, 94805, France|St. James University Hospital, Leeds, LS9 7TF, United Kingdom Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.77mL

0.55mL

0.28mL

13.83mL

2.77mL

1.38mL

27.66mL

5.53mL

2.77mL

References

 

Historical Records

Categories